HORMONES |
||
|---|---|---|
| MEDICATION | DOSAGE, ROUTE, FREQUENCY | INDICATIONS |
| Altrenogest (Regu-Mate®) (2.2 mg/ml) |
0.044 mg/kg, orally, q 24h
|
Suppression of behavioral estrus, synchronization of estrus, maintenance of pregnancy |
| Altrenogest (Regu-Mate®) (2.2 mg/ml) |
0.088 mg/kg, orally, q 24h or 0.044 mg/kg, orally, q 12h
(double dose)
|
Maintenance of pregnancy in high risk mares |
| Buserelin* | 10 to 50 µg, IM, q 6 h to 12h | GnRH agonist; stimulation of follicular development in anestrous, transitional or acyclic mares |
| Cloprostenol (Estrumate®) (250 µg/ml) | 250 µg, IM, once; or 50 µg, IM, q 24h for 2 to 3 days | Termination of luteal activity, synchronization of estrus, termination of pregnancy, stimulation of uterine contractions (evacuation of uterine fluid); should not be administered in the early post-ovulation period due to adverse effects on development of the corpus luteum |
| Deslorelin acetate (SucroMate™) (1.8 mg/ml) | 1.8 mg, IM, once | Induction of ovulation |
| Deslorelin acetate (low dose) | 50 to 100 µg, IM, q 12h | GnRH agonist; stimulation of follicular development in anestrous, transitional or acyclic mares |
| Dinoprost tromethamine (Lutalyse®) (5 mg/ml) | 5 to 10 mg, IM, once | Termination of luteal activity; synchronization of estrus, termination of pregnancy, stimulation of uterine contractions (evacuation of uterine fluid); should not be administered in the early post-ovulation period due to adverse effects on development of the corpus luteum |
| Domperidone (Equidone® Gel) (110 mg/ml) |
1.1 mg/kg, PO, q 12 to 24h
|
Dopamine antagonist; stimulation of lactation (agalactia) in postpartum mares, induction of lactation in nonpregnant mares, treatment of fescue toxicity |
| Estradiol (E2) | 5 to 10 mg, IM, q 24h | Stimulation of behavioral estrus in non-cycling or ovariectomized mares; used in conjunction with progesterone for estrus synchronization; pre-treatment of mares prior to domperidone therapy for induction of lactation |
| Estradiol cypionate (ECP) | 10 mg, IM, as needed | Stimulation of behavioral estrus in ovariectomized mares (long acting) |
| Human Chorionic Gonadotropin (hCG) (Chorulon®) (10,000 IU/vial) | 2,500 IU, IV or IM, once (dose range 1,500 to 3,000 IU) | Induction of ovulation |
| Human Chorionic Gonadotropin (hCG) (Chorulon®) (10,000 IU/vial) | 10,000 IU, IV or IM, once | hCG stimulation test to evaluate horse for presence of testicular tissue (testosterone response test) |
| Gonadotropin releasing hormone (GnRH) - native | 500 µg, IV or IM, once, 1 to 2 hours prior to breeding or collection | Increase libido in stallions with low libido |
| Oxytocin (20 units/ml) | 20 units, IV or IM, q 6h to q 24h or as needed | Stimulation of uterine contractions (evacuation of uterine fluid), treatment of retained placenta, milk let-down |
| Oxytocin (low dose) (20 units/ml) | 5 to 10 units, IV or IM, as needed | Induction of labor; administer 5 units followed by 10 units 15 minutes later; a majority of full term mares will rupture their chorioallantoic membrane within 5 to 15 minutes after the second dose of oxytocin |
| Progesterone-in-oil (P4) (50 or 100 mg/ml) | 150 mg, IM, q 24h | Suppression of behavioral estrus; synchronization of estrus and ovulation |
| Progesterone-in-oil (P4) (50 or 100 mg/ml) | 200 mg, IM, q 24h | Maintenance of pregnancy |
| Progesterone (long acting) (300 mg/ml) | 1,500 mg, IM, q 7 days | Suppression of behavioral estrus, synchronization of estrus, maintenance of pregnancy |
| Progesterone/Estradiol (P&E) | 150 mg P4/5 to 10 mg E2, IM, q 24h | Synchronization of estrus, ‘programming’ time of ovulation in transitional mares, suppression of estrus |
| Prostaglandin E1 (Misoprostol; Cytotec®) (100 µg/tablet) | 1,000 to 2,000 µg, topically onto cervix and within cervical lumen, as needed | Cervical relaxation; tablets are crushed and added to DMSO gel or sterile obstetrical gel and applied to the surface and lumen of the cervix |
| Prostaglandin E2 (dinoprostone cervical gel; Prepidil Gel® (0.2 mg/ml) | 1.0 mls gel applied to surface of each oviduct | Applied to surface of oviducts via laparoscope to ‘unblock’ oviducts suspected of luminal blockage with gelatinous masses that contain fibroblast cells |
| Sulpiride 5 % suspension (50 mg/ml)* |
0.5 to 1.0 mg/kg, IM, q 12h to q 24h
|
Dopamine antagonist; stimulation of lactation in postpartum mares; induction of lactation in nonpregnant mares; stimulation of follicular development in transitional mares |
*medication reported to be used at other facilities; not in use at CSU
